We use cookies to enhance your experience. By continuing to browse this site you agree to our use of cookies. More info.
Scientists at Duke-NUS Medical School in Singapore have uncovered a mechanism that leads to an advanced form of fatty liver disease-;and it turns out that vitamin B12 and folic acid supplements could reverse this process.
These findings could help people with non-alcoholic fatty liver disease, an umbrella term for a range of liver conditions affecting people who drink little to no alcohol, which affects 25 per cent of all adults globally, and four in 10 adults in Singapore.
Non-alcoholic fatty liver disease involves fat build-up in the liver and is a leading cause of liver transplants worldwide. Its high prevalence is due to its association with diabetes and obesity – two major public health problems in Singapore and other industrialized countries. When the condition progresses to inflammation and scar tissue formation, it is known as non-alcoholic steatohepatitis (NASH).
"While fat deposition in the liver is reversible in its early stages, its progression to NASH causes liver dysfunction, cirrhosis and increases the risk for liver cancer," said Dr Madhulika Tripathi, first author of the study, who is a senior research fellow with the Laboratory of Hormonal Regulation at Duke-NUS' Cardiovascular & Metabolic Programme.
Currently, there are no pharmacological treatments for NASH because scientists don't understand the mechanics of the disease. Although scientists know that NASH is associated with elevated blood levels of an amino acid called homocysteine, they didn't know what role, if any, it plays in the development of the disorder.
Dr Tripathi, study co-author Dr Brijesh Singh and their colleagues in Singapore, India, China and the US confirmed the association of homocysteine with NASH progression in preclinical models and humans. They also found that, as homocysteine levels increased in the liver, the amino acid attached to various liver proteins, changing their structure and impeding their functioning. In particular, when homocysteine attached to a protein called syntaxin 17, it blocked the protein from performing its role of transporting and digesting fat (known as autophagy, an essential cellular process by which cells remove malformed proteins or damaged organelles) in fatty acid metabolism, mitochondrial turnover, and inflammation prevention. This induced the development and progression of fatty liver disease to NASH.
Importantly, the researchers found that supplementing the diet in the preclinical models with vitamin B12 and folic acid increased the levels of syntaxin 17 in the liver and restored its role in autophagy. It also slowed NASH progression and reversed liver inflammation and fibrosis.
"Our findings are both exciting and important because they suggest that a relatively inexpensive therapy, vitamin B12 and folic acid, could be used to prevent and/or delay the progression of NASH," said Dr Singh. "Additionally, serum and hepatic homocysteine levels could serve as a biomarker for NASH severity."
Homocysteine may similarly affect other liver proteins, and finding out what they are is a future research direction for the team. They hope that further research will lead to the development of anti-NASH therapies.
Professor Paul M. Yen, Head of the Laboratory of Hormonal Regulation at Duke-NUS' Cardiovascular & Metabolic Disorders Programme, and senior author of the study, said, "The potential for using vitamin B12 and folate, which have high safety profiles and are designated as dietary supplements by the US Food and Drug Administration, as first-line therapies for the prevention and treatment of NASH could result in tremendous cost savings and reduce the health burden from NASH in both developed and developing countries."
Currently, the only treatment for patients with end-stage liver disease is to receive a transplant. The findings by Dr Tripathi and her colleagues demonstrate that a simple, affordable and accessible intervention could potentially halt or reverse the damage to the liver, bringing new hope to those suffering from fatty liver diseases. The team's findings underscore the value of basic scientific research, through which the scientific community continues to have a major positive impact on the lives of patients."
Professor Patrick Casey, Senior Vice-Dean for Research at Duke-NUS
The research was published in the Journal of Hepatology.
Tripathi, M., et al. (2022) Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing Syntaxin 17 homocysteinylation. Journal of Hepatology. doi.org/10.1016/j.jhep.2022.06.033.
Posted in: Medical Science News | Medical Research News | Medical Condition News
Tags: Alcohol, Amino Acid, Autophagy, Biomarker, Blood, Cancer, Cirrhosis, Diabetes, Diet, Fatty Liver, Fibrosis, Folic Acid, Food, Fructose, Hepatology, Homocysteine, Inflammation, Laboratory, Liver, Liver Cancer, Liver Disease, Medical School, Metabolic Disorders, Metabolism, Obesity, Pathology, Preclinical, Protein, Public Health, Research, Scar, Supplements, Transplant, Vitamin B12
We speak to Ali Safavi, CEO and Founder of Grenova about sustainable science, the impact life sciences research is having on our planet, and the solutions they offer for laboratories to help reduce their plastic waste.
In this interview, we speak to Charles Wells from Gates MRI about their current research into tuberculosis (TB) as well as the recent updated guidelines for TB care.
In this interview, we speak to Dr. Jordan Green about his latest research partnership with Modality.AI that investigated whether an app could be used to effectively diagnose speech decline due to ALS.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
This site complies with the HONcode standard for trustworthy health information: verify here.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2022